



Imaging biomarkers are key to detecting and treating cancer

Press Release

MEDIAN Technologies to take part in the Annual 2013 Conference of RSNA in Chicago

MEDIAN Technologies booth #3849, French Pavilion, South Building – Hall A

Sophia Antipolis, France – November, 29 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and service provider for image interpretation and management in oncology clinical trials and clinical routine, will participate in the Annual Meeting of the Radiological Society of North America (RSNA), to be held next Dec. 1-6, in Chicago, USA.

MEDIAN Lesion Management Solutions (LMS) for CT imaging, as well as new prototypes of clinical applications for other imaging modalities, will be presented in the MEDIAN booth #3849, French Pavilion, South Building, Hall A all along the conference.

The Annual Meeting of the Radiological Society of North America is the worldwide scientific and technical meeting of the medical imaging professional community. More than 60.000 professionals of the medical imaging will attend.

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world's largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechologies.com



MEDIAN

Imaging biomarkers are key to detecting and treating cancer

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO

+33 492 906 582

fredrik.brag@mediantechnologies.com

Press

ALIZE RP

Caroline Carmagnol

+ 33 664 189 959

caroline@alizerp.com

Christian Berg

+ 33 170 225 386

christian@alizerp.com